HKUST polymer-therapeutics platform entering the clinic in dry eye, with osteoarthritis and aesthetics as follow-on indications.
HKUST polymer therapeutics with a first-in-human trial authorised: Asian clinical-stage biotech like BILIX.
Evidence from the records
- “Polymer-based therapeutics (ophthalmology, osteoarthritis, regenerativ”
- “Series A”
- Intro path
- BILIX founders.
- First step
- Ask BILIX about WeVentures' biotech mandate.